重症喘息のステロイド抵抗性とその制御
Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers from strong symptoms on a daily basis despite all therapeutic agents used in combination. American SARP and European ENFUMOSA started in 2000...
Saved in:
Published in | 日本薬理学会年会要旨集 p. 2-S27-3 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | Japanese |
Published |
公益社団法人 日本薬理学会
2022
|
Subjects | |
Online Access | Get full text |
ISSN | 2435-4953 |
DOI | 10.1254/jpssuppl.95.0_2-S27-3 |
Cover
Abstract | Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers from strong symptoms on a daily basis despite all therapeutic agents used in combination. American SARP and European ENFUMOSA started in 2000 to advance pathophysiological insights of severe asthma. Clinical usage of antibodies and inhibitors against IgE, TNF, IL-5, IL-4, IL-13, and TSLP are also accumulating. Some of these molecular-targeted drugs improve respiratory function and reduce acute exacerbations in patients with severe asthma. Until now, cytokines have been assumed to be involved in chronic inflammation, but it is also interesting to elucidate the pathways of how cytokines are involved in respiratory function and acute exacerbations. We registered approximately 100 steroid-dependent asthma patients in Japan. Although long-lasting poor control of the disease was considered the cause of severe asthma in the past, steroid dependence in one third of the cases occurred within 2-3 years after the onset. Steroid resistance seems a key process from the early stage of the disease. Steroid resistance of T cell level was induced by extracellular co-stimulation and cytokine signals. The inhibition may improve steroid sensitivity and treat steroid-resistant asthma. Therefore, we established a steroid-resistant asthma model for the first time by transferring steroid resistant T cell clones, and analyzed the steroid sensitivity recovery effect of CTLA4-Ig. In addition, a multicenter, double-blind, placebo-controlled exploratory trial was performed as a POC study investigating the efficacy of abatacept in treatment-resistant severe asthma. Elucidation of the pathophysiology and mechanism by which steroids do not work is expected to be a breakthrough for the prevention and treatment of severe asthma. |
---|---|
AbstractList | Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers from strong symptoms on a daily basis despite all therapeutic agents used in combination. American SARP and European ENFUMOSA started in 2000 to advance pathophysiological insights of severe asthma. Clinical usage of antibodies and inhibitors against IgE, TNF, IL-5, IL-4, IL-13, and TSLP are also accumulating. Some of these molecular-targeted drugs improve respiratory function and reduce acute exacerbations in patients with severe asthma. Until now, cytokines have been assumed to be involved in chronic inflammation, but it is also interesting to elucidate the pathways of how cytokines are involved in respiratory function and acute exacerbations. We registered approximately 100 steroid-dependent asthma patients in Japan. Although long-lasting poor control of the disease was considered the cause of severe asthma in the past, steroid dependence in one third of the cases occurred within 2-3 years after the onset. Steroid resistance seems a key process from the early stage of the disease. Steroid resistance of T cell level was induced by extracellular co-stimulation and cytokine signals. The inhibition may improve steroid sensitivity and treat steroid-resistant asthma. Therefore, we established a steroid-resistant asthma model for the first time by transferring steroid resistant T cell clones, and analyzed the steroid sensitivity recovery effect of CTLA4-Ig. In addition, a multicenter, double-blind, placebo-controlled exploratory trial was performed as a POC study investigating the efficacy of abatacept in treatment-resistant severe asthma. Elucidation of the pathophysiology and mechanism by which steroids do not work is expected to be a breakthrough for the prevention and treatment of severe asthma. |
Author | 岩本, 圭右 永山, 貴紗子 松元, 幸一郎 濱田, 祐斗 谷本, 安 矢野, 光一 神沼, 修 大友, 暁美 関谷, 潔史 福富, 友馬 森, 晶夫 組谷, 千恵美 小林, 信之 大友, 隆之 上出, 庸介 渡井, 健太郎 中村, 祐人 神山, 智 藤田, 教寛 岩田, 真紀 山口, 美也子 劉, 楷 |
Author_xml | – sequence: 1 fullname: 谷本, 安 organization: 国立病院機構南岡山医療センター – sequence: 1 fullname: 山口, 美也子 organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部 – sequence: 1 fullname: 大友, 暁美 organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部 – sequence: 1 fullname: 大友, 隆之 organization: 東京薬科大・薬・臨床医療薬学センター – sequence: 1 fullname: 中村, 祐人 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 濱田, 祐斗 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 岩本, 圭右 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 永山, 貴紗子 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 矢野, 光一 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 神山, 智 organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部 – sequence: 1 fullname: 森, 晶夫 organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部 – sequence: 1 fullname: 岩田, 真紀 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 小林, 信之 organization: 国立病院機構東京病院 – sequence: 1 fullname: 関谷, 潔史 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 組谷, 千恵美 organization: 国立病院機構相模原病院・臨床研究センター・先端技術開発研究部 – sequence: 1 fullname: 上出, 庸介 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 渡井, 健太郎 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 藤田, 教寛 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 松元, 幸一郎 organization: 九州大・医・胸部疾患研究所 – sequence: 1 fullname: 神沼, 修 organization: 広島大・原爆放射線医科学研究所・疾患モデル解析研究分野 – sequence: 1 fullname: 劉, 楷 organization: 国立病院機構相模原病院・アレルギー呼吸器科 – sequence: 1 fullname: 福富, 友馬 organization: 国立病院機構相模原病院・アレルギー呼吸器科 |
BookMark | eNo9j8tKw0AARQdRsNZ-gp-QOM8ks5RiVSi4UNfDzGSiCbGGpC7cmRasFtxaNy4EQTfqSsGNPzMk4l8Y8bG5lwuHC2cJzA-OBgaAFQRdhBldTbKiOM6y1OXMhQI7O9h3yBxoYUqYQzkji6BTFLGClPqMMsRbwPucXH7MJtXVdV0-2_LJjt7s-MyOH-3ozo4v6ulLPZ3Vp_e2fLDlTQNU56_V--0yWIhkWpjOb7fBXm99t7vp9Lc3trprfSdBHoaOhFIrQrGJuBeEyOcaSU1DGjCqAhOqkDOuODEk0ko3i0tIpEcggh4zNFKkDXo_v0kxlPtGZHl8KPMTIfNhrFMj_owFZwJ-BxaNtCD_gD6QuUgk-QIxy2rR |
ContentType | Journal Article |
Copyright | 2022 本論文著者 |
Copyright_xml | – notice: 2022 本論文著者 |
DOI | 10.1254/jpssuppl.95.0_2-S27-3 |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2435-4953 |
ExternalDocumentID | article_jpssuppl_95_0_95_2_S27_3_article_char_ja |
GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF RJT |
ID | FETCH-LOGICAL-j1620-a0acb342ef968d179c1ac4d4854b8edbd959b93e3fcbcbd99a03a6301065e4fb3 |
IngestDate | Wed Sep 03 06:30:46 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Japanese |
LinkModel | OpenURL |
MeetingName | 日本薬理学会年会要旨集 第95回日本薬理学会年会 |
MergedId | FETCHMERGED-LOGICAL-j1620-a0acb342ef968d179c1ac4d4854b8edbd959b93e3fcbcbd99a03a6301065e4fb3 |
Notes | 95_2-S27-3 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/jpssuppl/95/0/95_2-S27-3/_article/-char/ja |
ParticipantIDs | jstage_primary_article_jpssuppl_95_0_95_2_S27_3_article_char_ja |
PublicationCentury | 2000 |
PublicationDate | 2022 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – year: 2022 text: 2022 |
PublicationDecade | 2020 |
PublicationTitle | 日本薬理学会年会要旨集 |
PublicationYear | 2022 |
Publisher | 公益社団法人 日本薬理学会 |
Publisher_xml | – name: 公益社団法人 日本薬理学会 |
SSID | ssib044754519 ssj0003321863 ssib041654217 |
Score | 1.8601602 |
Snippet | Asthma therapy in general has improved a lot in recent years, but it is still a major problem that severe asthma, which accounts for 10 to 20%, still suffers... |
SourceID | jstage |
SourceType | Publisher |
StartPage | 2-S27-3 |
SubjectTerms | allergy |
Title | 重症喘息のステロイド抵抗性とその制御 |
URI | https://www.jstage.jst.go.jp/article/jpssuppl/95/0/95_2-S27-3/_article/-char/ja |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | 日本薬理学会年会要旨集, 2022, pp.2-S27-3 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na9RAFA-1XryIouI3PTgnSc1mMl8nmdlmKUK92EJvIZNkD3uoRbYXD-K2YLXg1XrxIAh6UU8KHvSfCV3xv_C9yaQbpKCtEIa3kze_-e287L73hplJENwacmETCBVC3KYICUrOQmWZCEsqhKh4AUExTg2s3OfLa8m9dbY-d-p7Z9XS1tguFo-P3FdyEqtCHdgVd8kew7KHoFABMtgXSrAwlP9kY5IqAsm8XCKpIEqgnDKiOFGSpByCRKIHJKVOSJ0QE6OcABf3gl7yt3TS3lKuuSaGeQHAUYiIFi2g9IJa6nTBiJTEcBRMSnSvG_siAuBoh6n6RPdJKpEtCsA_cpQY8tEgJMT0idIOShGTdGokKkCPHlDiOChD5OEsI6qYiBgx6woeJQeeEqlmaoDdwwuJD4imjZpA8jJ1PQLywLNSUbchjJYWvqE0TUOO9JCYR_ibvnL63HckTXcOJp7l6q4Va8fJoEFAAEDjhhxqgDl0bihRzIGB6fTtkw1447Kdb4ghyg1xaXDX94QPYnAYR_rFmCXoFzfhtwzJzaJii1HW0f_jyHH_QGetfqZYFmERZ9Ako1mrgDsDsxGkJ6djIXq4onblSdr-nSe4US6eZc94tCQeZnQ4BUopvhCN-n11QPHOkQQhNhxBptSusnSB3-q54KzP2BZ0Q-Z8MDfKLwT81-7Ln_u7B69eTyef68mnevtbvfOs3vlYb7-rd15M975M9_anT9_Xkw_15A0oHDz_evDj7cVgbZCu9pdD_wqScNTjcRTmUV5YmsTVUHFZgvMqenmRlIlkiZVVaUvFlFW0osPCFvBJ5RHNOcWJFlYlQ0svBfMbDzeqy8GCyjkkU8zGAqLm3DI5ZJEtaTmkUVxWIr8S3G2-ZrbZnDOTHdcMV_8b4VpwBh_vZorxejA_frRV3YCge2xvOtP-BpboqAU |
linkProvider | ISSN International Centre |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%87%8D%E7%97%87%E5%96%98%E6%81%AF%E3%81%AE%E3%82%B9%E3%83%86%E3%83%AD%E3%82%A4%E3%83%89%E6%8A%B5%E6%8A%97%E6%80%A7%E3%81%A8%E3%81%9D%E3%81%AE%E5%88%B6%E5%BE%A1&rft.jtitle=%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A%E5%B9%B4%E4%BC%9A%E8%A6%81%E6%97%A8%E9%9B%86&rft.au=%E8%B0%B7%E6%9C%AC%2C+%E5%AE%89&rft.au=%E5%B1%B1%E5%8F%A3%2C+%E7%BE%8E%E4%B9%9F%E5%AD%90&rft.au=%E5%A4%A7%E5%8F%8B%2C+%E6%9A%81%E7%BE%8E&rft.au=%E5%A4%A7%E5%8F%8B%2C+%E9%9A%86%E4%B9%8B&rft.date=2022&rft.pub=%E5%85%AC%E7%9B%8A%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E8%96%AC%E7%90%86%E5%AD%A6%E4%BC%9A&rft.eissn=2435-4953&rft.spage=2-S27-3&rft_id=info:doi/10.1254%2Fjpssuppl.95.0_2-S27-3&rft.externalDocID=article_jpssuppl_95_0_95_2_S27_3_article_char_ja |